Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab With or Without Standard Chemotherapy in Advanced or Metastatic Colorectal Cancer
2021-006629-23Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in colorectal cancer (CRC) and metastatic colon cancer (mCRC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Objective response rate. Started May 2022; status: active.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2021-006629-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006629-23.